Effects of platelet-activating factor on electrophysiology of isolated retinas and their inhibition by BN 52021, a specific PAF-acether receptor antagonist

Doly, M.; Bonhomme, Brigitte; Braquet, P.; Chabrier, Pierre‐Etienne; Meyniel, G

doi:10.1016/0162-3109(87)90057-9

Cited by 19 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synthesis of PAF by retinal tissue has been demonstrated by Bussolino et al (16) and confirmed by Rosenbaum et al (17), who also obtained enhanced production of PAF in an experimental uveitis model. The role of PAF in the retina is not yet elucidated, but it is known that injection of PAF into the retinal artery induces intense vasoconstriction (18), and that administration of PAF in the liquid perfusing an isolated retina causes irreversible collapse of the ERG (19). The inhibition of these effects with specific antagonists suggested the existence of receptors, which was confirmed subsequently (20).…”

Section: Discussionmentioning

confidence: 94%

Experimental Electroretinographic Exploration of Retinal Ischemia: Preventive Use of Free Radical Scavengers and Anti-PAF Agents

Cluzel²,

Mt³

et al. 1997

Journal of Ocular Pharmacology and Therapeutics

Self Cite

View full text Add to dashboard Cite

Electroretinographic exploration is an effective approach to evaluate retinal function. In order to investigate physiopathological mechanisms and evaluate potentially protective therapies for retinal ischemia, we developed three experimental models: the first two on isolated retina, with ischemia induced by either stopping perfusion or clamping the ophthalmic artery, and the third, in vivo, with ischemia induced by ocular hypertonia. Since free radicals are implicated in the formation of postischemic lesions, we evaluated the protective effects of drugs known to be free radical scavengers and of an immunomediator antagonist, an anti-PAF (platelet activating factor) agent.

show abstract

Section: Discussionmentioning

confidence: 94%

Experimental Electroretinographic Exploration of Retinal Ischemia: Preventive Use of Free Radical Scavengers and Anti-PAF Agents

Cluzel²,

Mt³

et al. 1997

Journal of Ocular Pharmacology and Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The relative absence of a critical enzyme to degrade PAF in the retina may explain its susceptibility to PAF-induced effects (36). Interestingly PAF is believed to be a possible neurotransmitter in the retina (37), where it appears to be locally synthesized (38)(39)(40). Microglia (41) and the endothelium of cerebral vessels (42) are also known producers of PAF.…”

Section: Discussionmentioning

confidence: 99%

Intravitreally injected platelet activating factor induces retinitis in experimental animals

Rosenbaum¹,

Angell²,

Wilson³

et al. 1999

Current Eye Research

View full text Add to dashboard Cite

show abstract

“…Here, PAF seems to be implicated in the retinopathy, which is a limited, narrowly localised inflammation of the functional layers of the retina. PAF apparently acts as a mediator of localised toxic damage at the level of the retinal function (ERG) (Doly et al 1987). Accordingly, agents such as BN SO730 that possess PAF antagonist properties should find use in the prevention of…”

Section: Discussionmentioning

confidence: 99%

Protective effect of a specific PAF antagonist on vincristine‐induced experimental retinopathy

Doly

Cluzel

Bonhomme

et al. 1995

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

The alkaloid vincristine displays considerable toxicity, particularly for the retina. This type of retinopathy being an inflammatory disease, we measured the effects of a new hetrazepine platelet activating factor antagonist, BN 50730, on a vincristine-induced retinopathy in the rat. Retinal impairments were established by recording several parameters of the electroretinogram obtained from isolated retina. Our results indicate that 1) the increase in PIII duration induced by vincristine is significantly reduced by BN 50730 administration 2) the decrease in the amplitude of the PIII/b wave ratio caused by vincristine is partially inhibited by treatment with BN 50730. These experiments suggest that platelet activating factor is implicated in vincristine retinopathy and demonstrate the therapeutic effect of a specific antagonist of the mediator.

show abstract

Effects of platelet-activating factor on electrophysiology of isolated retinas and their inhibition by BN 52021, a specific PAF-acether receptor antagonist

Cited by 19 publications

References 21 publications

Experimental Electroretinographic Exploration of Retinal Ischemia: Preventive Use of Free Radical Scavengers and Anti-PAF Agents

Experimental Electroretinographic Exploration of Retinal Ischemia: Preventive Use of Free Radical Scavengers and Anti-PAF Agents

Intravitreally injected platelet activating factor induces retinitis in experimental animals

Protective effect of a specific PAF antagonist on vincristine‐induced experimental retinopathy

Contact Info

Product

Resources

About